Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.
6
Study Matches
Phase II Study of Bendamustine and Rituximab plus Venetoclax in Untreated Mantle Cell Lymphoma over 60 Years of Age
This study is to see if venetoclax in combination with bendamustine and rituximab chemotherapy is effective in treating people who have mantle cell lymphoma and to examine the side effects, good and bad, associated with this combination .
Must have histologically confirmed (biopsy-proven) diagnosis of mantle cell lymphoma (MCL) Must have measurable or evaluable disease as defined as a lymph node measuring >1.5 cm in any dimension or splenomegaly with spleen >15 cm in craniocaudal dimension ECOG performance status of 0-2 Adequate organ function as measured by the criteria Total Bilirubin ≤ 1.5x upper limit of normal (ULN) or ≤ 3x ULN with documented Gilbert’s syndrome
Exclusion Criteria:
Should not have known evidence of central nervous system (CNS) lymphoma Should not have prior chemotherapy, radiotherapy or immunotherapy for lymphoma Must not have received a prior allogeneic stem cell transplant or solid organ transplant (except for cornea) for any indication Must have no active, uncontrolled infections Must not have active hepatitis B or be chronic carriers of hepatitis B.
Risk-based, response-adapted, Phase II open-label trial of nivolumab + brentuximab vedotin (N + Bv) for children, adolescents, and young adults with relapsed/refractory (R/R) CD30 + classic Hodgkin lymphoma (cHL) after failure of first-line therapy, followed by brentuximab + bendamustine (Bv + B) for participants with a suboptimal response.
CheckMate 744: CHECKpoint pathway and nivolumab clinical Trial Evaluation
This is is a Phase 2, open-label study of nivolumab and brentuximab for children and young adults with relapsed/refractory classic Hodgkin lymphoma.
An Open Label, Randomized, Multicenter, Phase Ib/II Trial Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination with Polatuzumab Vedotin in patients with B-Cell Non-Hodgkin Lymphoma(GO40516)(PSCI18-058)
This is a drug study that will compare drug mosunetuzumab with drug polatuzumab vedotin in patients with non-Hodgkin lymphoma (NHL).
Must have received at least one prior systemic treatment regimen containing an anti-CD20 directed therapy for DLBCL or FL. Life expectancy of at least 12 weeks Measurable disease, defined as at least one bi-dimensionally measurable nodal lesion, defined as > 1.5 cm in its longest dimension, or at least one bi-dimensionally measurable extranodal lesion, defined as > 1.0 cm in its longest dimension Adverse events from prior anti-cancer therapy resolved to < or = Grade 1 Hepatic Function: < or =AST and ALT < or = 2.5 x ULN; total bilirubin < or = 1.5 x ULN
Exclusion Criteria:
Pregnant or breastfeeding, or intending to become pregnant during the study or within 3 months Prior treatment with mosunetuzumab or other CD20-directed bispecific antibodies Prior treatment with polatuzumab vedotin Prior use of any monoclonal antibody, radioimmunoconjugate or ADC within 4 weeks before first dose of study treatment Treatment with any chemotherapeutic agent, or treatment with any other anti-cancer agent (investigational or otherwise) within 4 weeks or 5 half-lives of the drug, whichever is shorter, prior to first dose of study treatment
Managed Access Program (MAP) to provide access to CTL019, for acute lymphoblastic leukemia (ALL) or large B-cell lymphoma patients with out of specification leukapheresis product and/or manufactured tisagenlecleucel out of specification for commercial release
This study is to provide access to CTL019 for ALL or large B-cell lymphoma patients who are either out of manufactured specifications or out of specification leukapheresis product who would otherwise not be able to be treated with CTL019 due to commercial restrictions.
This means these manufactured cells are not able to be used commercially and insurance will not pay or contribute to paying for the product.
patient to be treated has a serious or life threatening disease or condition and no comparable alternative therapy is available patient is not eligible or able to enroll in a clinical trial potential benefit to justify potential risk of the treatment use provision of the investigational product will not interfere with the initiation, conduct or completion of a Novartis clinical trial access to provision of investigational product is allowed per local laws and regulations
Exclusion Criteria:
product can be commercially manufactured per the specifications evidence of CD19 negative disease in patients with B-cell ALL active Hepatitis B, active or latent Hepatitis C, or HIV positivity uncontrolled active infection or inflammation pregnant or nursing women
E4512- A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Purpose of this study is to compare any good and bad effects of using the study drug, crizotinib after completeion of surgery and in some cases after chemotherapy and/or radiation therapy for ALK-positive non-small cell lung cancer.
Patients must have undergone complete surgical resection of their Patients must be registered to the ALCHEMIST-SCREEN (ALLIANCE ALK positive Patients must have completed any prior adjuvant chemotherapy or
Exclusion Criteria:
No prior treatment with crizotinib or another ALK inhibitor.
A Phase III Randomized, Open Label, Multi-center Study of the Safety and Efficacy of Apixaban for Venous Thromboembolism Prevention versus No Systemic Anticoagulant Prophylaxis during Induction Chemotherapy in Children with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (T or B cell) Treated with Pegylated Asparaginase
A study to confirm and expand information on safety and effectiveness of apixaban to prevent blood clots as compared to no prevention treatment in children with newly diagnosed leukemia and lymphoma. This is a randomized study so patients will be selected by chance to be in either the group that receives apixaban or the group that does not receive apixaban.
New diagnosis of leukemia (de novo ALL) or lymphoma (T or B cell). An acceptable planned induction chemotherapy. One year of age and older to less than 18 years of age. Able to take oral medication or have it given through a tube.
Exclusion Criteria:
Had a blood clot in the past 3 months. Known inherited bleeding disorder.